Analogue of the nucleoside cytidine. Originally developed as a chemotherapeutic drug for cancer, it is licensed for use for treatment of myelodysplastic syndrome. Its effects may be mediated by two mechanisms: firstly, a direct cytotoxicity through incorporation of the drug into RNA/DNA synthesis, and secondly, inhibition of DNA methyltransferase, resulting in hypomethylation of previously epigenetically suppressed genes.
Cautions and Interactions
DNA methyltransferase inhibitor
- ↑ Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Aug 20; 24(24):3895-903.(Link to article – subscription may be required.)
- ↑ Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May 15; 11(10):3604-8.(Link to article – subscription may be required.)
This article is a work in progress. Please feel free to contribute to it.